arrow
S

Seong Hoon Yoon

pusan national university
H指数:18
被引数:1,024

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3–4 Pulmonary Nodules: A Multicenter Prospective Cohort Study

AptoDetect™-Lung检测试剂盒作为肺-RADS 3–4肺结节患者晚期肺癌的血液检测预测指标:一项多中心前瞻性队列研究

2026-04-300
OA
Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study

广泛期小细胞肺癌中一线阿替利珠单抗的扩展随访分析:一项真实世界多中心前瞻性队列研究

2025-12-110
OAAI
Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial

Bojungikki-Tang草药 medicine 联合 Pembrolizumab 与 Pembrolizumab 单药治疗对 IV 期非小细胞肺癌的疗效与安全性:一项随机、开放标签、双臂、多中心试验的研究方案

2025-02-220
OA
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data

真实世界一线阿法替尼治疗晚期EGFR突变阳性非小细胞肺癌: 更新的生存数据

2023-11-010
OAAI
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

EGFR突变非小细胞肺癌脑转移患者一线阿法替尼的真实世界分析: 生存和预后因素

2023-06-012
OAAI
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea

韩国阿法替尼一线治疗晚期EGFR突变阳性非小细胞肺癌的真实经验

2021-12-0111
OAAI